Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
13 nov. 2024 08h30 HE
|
Intelligent Bio Solutions, Inc.
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW...
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
23 oct. 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago
17 oct. 2024 08h29 HE
|
Alkeus Pharmaceuticals
Results from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During Retina Subspecialty Day Positive Data from TEASE...
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
27 sept. 2024 08h30 HE
|
Intelligent Bio Solutions, Inc.
INBS successfully completes in-clinic testing proposed to the FDA earlier this year in its clinical study plan.
Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission
05 sept. 2024 08h30 HE
|
Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
06 août 2024 08h00 HE
|
Science 37, Inc.
Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials.
Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway
01 août 2024 08h30 HE
|
Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions Inc. (INBS) partners with CenExel to perform a method comparison clinical study as part of the Company’s FDA clinical study plan.
Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success
18 juil. 2024 08h30 HE
|
Intelligent Bio Solutions, Inc.
NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe
23 juin 2023 08h01 HE
|
Ocean Biomedical, Inc.
Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic...
Clinical Trials Market to Surpass US$ 177.7 Billion Valuation by 2033 Owing to the Development of Precision Medicines and Therapeutic Approaches | Future Market Insights, Inc.
07 févr. 2023 08h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Feb. 07, 2023 (GLOBE NEWSWIRE) -- The global Clinical Trials Market is anticipated to augment at a flourishing CAGR of 4.41% over the forecast period from 2023 to 2033. The global...